Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDF Monotherapy in Antiretroviral-Naive HIV-1
NCT00016588Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- May 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenofovir disoproxil fumarate in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Primary endpoint: Change in plasma HIV-1 RNA at 21 days. Started May 2001; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00016588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016588.